AstraZeneca and Merck's PARP inhibitor Lynparza has carved out blockbuster revenues across uses in breast, ovarian, prostate and pancreatic cancer, but colorectal cancer won’t be added to t
Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting encouraging results when the drug is used alongside its EGFR drug Vectibix
The FDA has approved the first artificial intelligence-powered device that can be used to help identify colorectal lesions during the millions of colonoscopies carried out each year in the
Two months after rejecting Pierre Fabre’s Braftovi for a rare form of metastatic colorectal cancer (mCRC), NICE has changed its mind, and now says the drug can be funded by the NHS in Engla
It’s barely a month since Merck & Co unveiled trial results showing that cancer immunotherapy Keytruda (pembrolizumab) works in colorectal cancer patients with certain mutations, and th